[Featured Stock] Korea BNC Advances Development of 'Dream Obesity Drug' GLP-1 Agonist... 52-Week High

US Biotech Company Reports Positive GLP-1 Clinical Results
Boost in Treatment Market...Industry Stocks Highlighted
Korea BNC and ProAptech Collaborate on Agonist Development

Korea BNC is showing strong performance. This is interpreted as being influenced by positive clinical news regarding glucagon-like peptide-1 (GLP-1), the so-called "dream obesity drug." As a favorable wind blows through the obesity treatment market and related stocks gain attention, Korea BNC is receiving the greatest benefit with the added news of its development of a GLP-1 agonist.

As of 9:25 AM on the 29th, Korea BNC is trading at 5,190 KRW, up 13.94% (635 KRW) compared to the previous day. It surpassed the 52-week high of 4,860 KRW recorded in September 2023. Korea BNC's stock price rose from the start of trading that day and reached a high of 5,330 KRW.

The previous day, U.S. biotech company Therapeutics reported positive results in a Phase 2 clinical trial for an obesity treatment, causing its stock price to surge over 120%. The results showed a 14.7% reduction in patient weight after 13 weeks of GLP-1 administration. This outcome was better than the obesity treatment clinical results from Eli Lilly and Novo Nordisk.

GLP-1 is an incretin hormone secreted in response to nutrients in the gastrointestinal tract. It is characterized by enhancing insulin secretion according to glucose concentration. While it has a strong insulin secretion stimulation effect, it has the advantage of not causing hypoglycemia, making it a new candidate drug for obesity and diabetes treatment.

Following the favorable news of obesity treatments from the U.S., Korea BNC announced that it will jointly develop a GLP-1 "agonist" for diabetes and obesity treatment with ProApTech. The two companies plan to utilize ProApTech's proprietary 'SelecAll' technology to jointly develop and commercialize sustained-release candidate substances for GLP-1 agonists and target proteins for diabetes and obesity treatment. They will apply ProApTech's click chemistry and artificial intelligence (AI)-based non-natural amino acid insertion technology along with site-specific albumin binding technology.